News / US / cnbc
Johnson & Johnson Targets Robotic Surgery Dominance With New Ottava System
Health Technology · Medical Specialties · cnbc · 2026-09-11
JNJ, ISRG, IHI, MDT, XHE, XBI
J&J is entering the competitive robotic surgery market with its FDA-cleared Ottava system, aiming to challenge long-time leader Intuitive Surgical.
What Happened
Strategic Market Entry: Johnson & Johnson has officially entered the robotic surgery sector with its Ottava system, which recently secured FDA approval for various general procedures. The company aims to leverage its existing strength as a major supplier of surgical tools to gain a foothold in a market currently dominated by Intuitive Surgical's da Vinci platform.
Design and Competitive Edge: The Ottava system features a unique design with robotic arms integrated directly into the operating table, offering a significantly smaller footprint than traditional cart-based systems. Management believes this space-saving innovation, combined with potential product bundling opportunities, will appeal to hospitals looking to modernize their surgical suites without major infrastructure changes.
Market Growth and Challenges: While the global surgical robotics market is projected to reach over $50 billion by 2035, J&J faces a steep climb against incumbents like Intuitive Surgical and Medtronic. Analysts remain divided on the immediate impact of Ottava, citing potential production constraints and the long sales cycles inherent in capital-intensive hospital equipment procurement.
Financial Outlook and Focus: J&J views the MedTech division as a core growth driver, especially as it moves to divest its slower-growing orthopedics business. Although the company has not provided specific revenue targets for Ottava, leadership expects the program to become a material financial contributor by the end of the decade as it scales globally.